D
David Spiegel
Researcher at Stanford University
Publications - 838
Citations - 50967
David Spiegel is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 106, co-authored 733 publications receiving 46276 citations. Previous affiliations of David Spiegel include Tel Aviv University & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Morning chronotype is a protective factor against chemotherapy-induced hot flashes in premenopausal women with breast cancer.
Kyung Lak Son,Dooyoung Jung,Kwang Min Lee,Kwang Min Lee,Heesung Hwang,Jooyoung Lee,Tae Yong Kim,Tae Yong Kim,Seock-Ah Im,Seock-Ah Im,Seock-Ah Im,Kyung Hun Lee,Kyung Hun Lee,David Spiegel,Bong Jin Hahm +14 more
TL;DR: Morning chronotype is a protective factor against the development of chemotherapy-induced hot flashes in patients with breast cancer, and should be assessed and considered in the prediction and management of CIHF.
Journal ArticleDOI
Emotion regulation and metastatic breast cancer
Janine Giese-Davis,David Spiegel +1 more
TL;DR: Recently, a number of researchers have developed more specific self-report instruments, have conducted studies designed to estimate the separability of various aspects of emotion regulation, and have begun to understand the relationship between selfreport of emotions and behavioral observation of expression as mentioned in this paper.
Journal Article
Spontaneous hypnotic age regression: case report.
David Spiegel,Rosenfeld A +1 more
TL;DR: The psychiatric presentation and treatment of a 16-year-old girl with spontaneous age regressions accessible and controllable with hypnosis and psychotherapy are described.
Journal ArticleDOI
The Hypnotic Induction Profile (HIP) in Clinical Practice and Research.
TL;DR: The Hypnotic Induction Profile (HIP) as discussed by the authors was developed as a brief, yet thorough, assessment of a person's level of trait hypnotizability and their potential to experience a hypnotic state.
Journal ArticleDOI
LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial
M. Ahn,S Kim,Enric Carcereny Costa,Laura Rodriguez,Jéssyca Duarte de Oliveira,M.A. Insa Molla,Margarita Majem,Laís Silveira Costa,W. Su,K. Lee,J.C. Yang,David Spiegel,Eunyoung Cho,Manolo D’Arcangelo,Maria Rosario Garcia Campelo,Angelo Delmonte,Paul Mitchell,Ikbel Achour,Deepa S. Subramaniam,Enriqueta Felip +19 more
TL;DR: In this paper , the authors presented results in 1L non-squamous (Nsq) NSCLC from an ongoing phase 1b/2 study (NCT03530397), where patients were enrolled into randomized (R) and single arm (S) cohorts.